Hadassah

Peace in Sight: An Israeli, Palestinian, and Hadassah Australia Collaboration

Friday, Jan 13 2017

Peace in Sight participant.

St. John of Jerusalem Eye Hospital, in collaboration with Hadassah Medical Organization, has received a €500,000 grant from the European Union to establish a genetic research unit to serve the Palestinian communities.

St. John, established in 1885, has built a reputation for fine ophthalmic care in the region. The primarily Palestinian population that it serves faces many health challenges, not the least being serious eye disease, much of it driven by the very high incidence of consanguineous marriages.

The main missions of Peace in Sight are to:

·       Train a Palestinian ophthalmologist from St. John at Hadassah in molecular genetics and clinical management

·       Study in depth 100-200 Palestinians with hereditary eye diseases to identify the most common ones

·       Establish a fully functional Genetic Disease Laboratory at St John

·       Collect samples from recruited Palestinians and identify the most common genetic patterns of inherited ocular diseases in the Palestinian population

·       Provide counseling for prevention of disease transmission

·       Explore novel treatment modalities, including gene and cell-based therapies

·       Increase awareness of targeted beneficiaries on an individual basis and

·       Facilitate access or travel permits with the Israeli Civil Administration.

The grant of €500,000 for the three-year Peace in Sight project constitutes approximately 80 percent of the total project cost. Hadassah Australia is seeking to raise $50,000 to assist with the remainder. Toward that goal, Hadassah Australia recently held a luncheon at the RANZCO (Royal Australian and New Zealand College of Ophthalmologists) Conference to raise awareness and funds for Peace in Sight, which brought in over $10,000 for the project. Follow-up letters have also been sent out to ophthalmologists who could not attend to raise additional funds.

Ron Finkel, President of Hadassah Australia, reports: “We will be pursuing this campaign through the first quarter of 2017, culminating with the visit to Sydney in late March by Prof. Koby Pe’er, head of the Department of Ophthalmology at Hadassah.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Hadassah Removes Tumor;
Gazan Boy Walks for First Time

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More